BIOXIS Pharmaceuticals

  • News
  • Careers
  • Press
  • Contact
  • Home
  • Company
    • Strategic alliances
    • Partners
  • Technology
  • Products
    • MTI-12
  • Production & certification
  • Investors
  • Innovative Technology
    With Novel Biomimetic and Regenerative Scaffold

  • Technology

    Based on Ultrapure Chitosan, We Have Created a New Generation of Biomimetic and Regenerative Scaffold

    How does it work? Chitin (C8H13O5N)n was isolated and characterized in 1823 by Auguste Odier as a long-chain homopolymer of N-acetyl-d-glucosamine (GlcNAc), (1–4)-linked 2-acetamido-2-deoxy-β-d-glucan. Our technology is based on Chitosan; a nontoxic biopolymer produced by the deacetylation of chitin.

    Sound Complicated? Well, a Little, But that’s Where the Experts at Bioxis Come in…

    Using advanced techniques, Bioxis has developed a unique technology based on ultrapure chitosan, with outstanding physico-chemical and morphological properties. This makes it possible to:
    • Promote cell interactions
    • Mimic the extracellular matrix to enhance colonization by autologous cells
    • Facilitate tissue regeneration
  • Pipeline

    Bioxis' Active Research Programs
    Transform Doctors' Ability to Repair Soft Tissue...

    Our ongoing R&D efforts provide new formulations and additional indications to address unmet needs of aesthetic dermatology.

    • Technology
    • Product
    • Production & certification
BIOXIS pharmaceuticals
317 avenue Jean Jaurès
69007 Lyon, France
  • Home
  • Company
  • Technology
  • Products
  • Production & certification
  • Investors
  • News
  • Careers
  • Press
  • Contact
  • Legal notices
Logo region Auvergne Rhone Alpes
© Bioxis pharmaceuticals - White Chapel - ID-Alizés